GlaxoSmithKline

DelveInsight's report on PD-1 Non-Small Cell Lung Cancer Market (2020-2034) highlights market growth, approvals, prevalence, therapies, and companies like Merck, Bristol-Myers Squibb, Genentech, and others. Key therapies include KEYTRUDA, OPDIVO, TECENTRIQ, and TIZVENI. Market drivers include premium-priced targeted agents and therapy expansion, while barriers include premium pricing of emerging therapies.

Clinical trials lack diversity, with underrepresented groups like Black and Hispanic patients significantly underrepresented. The FDA's updated guidance on Diversity Action Plans aims to address this. Real-world data (RWD) and artificial intelligence (AI) can enhance diversity by revealing patterns in diverse populations and improving recruitment strategies. RWD and real-world evidence (RWE) can also monitor drug performance post-approval, ensuring more inclusive and representative clinical research.

New Amsterdam Pharma's CETP inhibitor succeeded in Phase 3 trials, GSK partnered with Relation for fibrotic disease and osteoarthritis drugs, Cardiff Oncology's CRDF-004 showed tumor shrinkage in metastatic colon cancer patients, and Cure Ventures launched Tasca Therapeutics with $52 million for cancer therapies. GSK's Blenrep showed improved survival in multiple myeloma patients, J&J's Darzalex may prevent myeloma in high-risk patients, and Uniqure received FDA approval to seek accelerated approval for Huntington's disease gene therapy.

GSK's Blenrep, an antibody-drug conjugate targeting BCMA in multiple myeloma, showed a 42% reduction in death risk when combined with chemotherapy and a steroid, compared to J&J's Darzalex. Despite initial market withdrawal, GSK is optimistic about Blenrep's potential comeback, supported by new survival data and ongoing studies. The drug could face competition from emerging cell therapies and bispecific antibodies, but GSK is exploring dosing options to enhance its profile.

23andMe, after a 99% stock drop and a data breach, has scrapped its drug R&D, cut 40% of its workforce, and seen its independent directors resign. The company is now focusing on strategic collaborations, launching new offerings, and navigating genetic data privacy concerns.

Eli Lilly's Phase III BRUIN CLL-321 study showed Jaypirca reduced relapse, disease progression, or death risk by 46% in CLL/SLL patients previously treated with covalent BTK inhibitors. Jaypirca also outperformed in secondary endpoints like progression-free survival and event-free survival. However, safety concerns emerged with a higher fatality rate in the Jaypirca group, though adjusted analysis showed a 13% lower risk of death.

GSK's Blenrep, a multiple myeloma drug, shows significant overall survival benefit in a Phase 3 study, potentially becoming a new standard of care treatment. The drug, an antibody drug conjugate targeting BCMA, demonstrated a 42% reduction in the risk of death compared to a standard regimen. Despite initial market withdrawal, new data supports its efficacy in earlier treatment lines, with ongoing FDA review expected in July.

Prostate cancer clinical trials need innovative approaches to better capture patient experience and improve treatment options, focusing on progression-free and disease-free survival as primary endpoints.

Johnson & Johnson seeks approval for Darzalex to treat high-risk smoldering myeloma, with AQUILA trial showing reduced risk of disease progression. GSK's Blenrep, after withdrawal, shows improved survival in DREAMM-7 trial. Emerging efforts aim to ease conditioning for genetic treatments in sickle cell disease. Kura Oncology's menin inhibitor shows promising results in AML, facing competition from J&J and Syndax. Pfizer's Oxbryta withdrawal for sickle cell disease remains unexplained.

Despite headwinds, the techbio sector continues to attract significant investment and drive innovation, exemplified by the 2024 launch of Xaira, backed by over $1 billion, aiming to design novel therapeutic proteins using advanced AI. The sector is maturing through strategic consolidation, significant capital deployment, technical diversification, and steady clinical validation, as illustrated by 25 techbio organizations, including notable players like Isomorphic Labs, Generate:Biomedicines, Recursion Pharmaceuticals, and Schrödinger Inc., all leveraging AI for drug discovery. Emerging players such as Archon Biosciences, AION Labs, and Antiverse are also making strides, while established companies like Insilico Medicine and Ginkgo Bioworks continue to expand their platforms and partnerships.